TScan Therapeutics (NASDAQ:TCRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $11.00 target price on the stock.

Other equities analysts also recently issued reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Trading Down 8.2 %

TScan Therapeutics stock opened at $4.82 on Tuesday. TScan Therapeutics has a 52 week low of $3.73 and a 52 week high of $9.69. The firm has a market capitalization of $255.32 million, a price-to-earnings ratio of -4.55 and a beta of 0.79. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.77 and a current ratio of 9.56. The company has a 50 day moving average price of $5.33 and a 200 day moving average price of $6.51.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.55 million. Research analysts forecast that TScan Therapeutics will post -1.17 EPS for the current year.

Insider Activity at TScan Therapeutics

In related news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. This trade represents a 97.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction on Monday, September 23rd. The stock was bought at an average price of $5.29 per share, with a total value of $26,450.00. Following the transaction, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. This represents a 12.50 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 15,000 shares of company stock worth $82,550. 2.76% of the stock is owned by insiders.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tocqueville Asset Management L.P. acquired a new stake in shares of TScan Therapeutics during the 1st quarter worth approximately $1,685,000. Vanguard Group Inc. grew its position in shares of TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after buying an additional 20,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $682,000. Rhumbline Advisers acquired a new position in TScan Therapeutics during the second quarter valued at approximately $274,000. Finally, American Century Companies Inc. grew its holdings in TScan Therapeutics by 48.9% during the second quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after purchasing an additional 15,596 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.